Microscopic Polyangiitis (MPA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Microscopic polyangiitis is an ill-defined autoimmune disease characterized by a systemic, pauci-immune, necrotizing, small-vessel vasculitis without clinical or pathological evidence of necrotizing granulomatous inflammation. The signs and symptoms of microscopic polyangiitis may resemble those of granulomatosis with polyangiitis (GPA) (another form of small-vessel vasculitis) but lack the significant upper respiratory tract involvement frequently seen in people affected by GPA.
The Microscopic Polyangiitis drugs in development market research report provides comprehensive information on the therapeutics under development for Microscopic Polyangiitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and the molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Microscopic Polyangiitis and features dormant and discontinued projects.
What are the key targets in the Microscopic Polyangiitis pipeline products market?
The key targets in the Microscopic Polyangiitis pipeline products market are Cells Expressing B Lymphocyte Antigen CD20 and Complement C5.
Microscopic Polyangiitis Pipeline Products Analysis Market by Targets
For more target insights, download a free report sample
What are the key mechanisms of action in the Microscopic Polyangiitis pipeline products market?
The key mechanisms of action in the Microscopic Polyangiitis pipeline products market are Cytotoxic to Cells Expressing B Lymphocyte Antigen CD20 and Complement C5 Inhibitor.
Microscopic Polyangiitis Pipeline Products Market Analysis by Mechanism of Actions
For more mechanism of actions insights, download a free report sample
What are the key routes of administration in the Microscopic Polyangiitis pipeline products market?
The key routes of administration in the Microscopic Polyangiitis pipeline products market are intravenous, parenteral, and subcutaneous.
Microscopic Polyangiitis Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
What are the different molecule types in the Microscopic Polyangiitis pipeline products market?
The different molecule types in the Microscopic Polyangiitis pipeline products market are monoclonal antibody and antibody.
Microscopic Polyangiitis Pipeline Products Market Analysis by Molecule Type
To know more about molecule types, download a free report sample
Which are the major companies in the Microscopic Polyangiitis pipeline products market?
The major companies in the Microscopic Polyangiitis pipeline products market are Biogen Inc, InflaRx NV, Mabion SA, Nanolek, Pharmapraxis, and Teijin Pharma Ltd.
Microscopic Polyangiitis Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
Market Report Scope
Key targets | Cells Expressing B Lymphocyte Antigen CD20 and Complement C5 |
Key mechanism of action | Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20 and Complement C5 Inhibitor |
Key routes of administration | Intravenous, Parenteral, and Subcutaneous |
Molecule type | Monoclonal Antibody and Antibody |
Major companies | Biogen Inc, InflaRx NV, Mabion SA, Nanolek, Pharmapraxis, and Teijin Pharma Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Microscopic Polyangiitis ((MPA) Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Microscopic Polyangiitis (MPA) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Microscopic Polyangiitis (MPA) (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Microscopic Polyangiitis (MPA) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Microscopic Polyangiitis (MPA) (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Microscopic Polyangiitis (MPA) (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Microscopic Polyangiitis pipeline products market?
The key targets in the Microscopic Polyangiitis pipeline products market are Cells Expressing B Lymphocyte Antigen CD20 and Complement C5.
-
What are the key mechanisms of action in the Microscopic Polyangiitis pipeline products market?
The key mechanisms of action in the Microscopic Polyangiitis pipeline products market are Cytotoxic to Cells Expressing B Lymphocyte Antigen CD20 and Complement C5 Inhibitor.
-
What are the key routes of administration in the Microscopic Polyangiitis pipeline products market?
The key routes of administration in the Microscopic Polyangiitis pipeline products market are intravenous, parenteral, and subcutaneous.
-
What are the different molecule types in the Microscopic Polyangiitis pipeline products market?
The different molecule types in the Microscopic Polyangiitis pipeline products market are monoclonal antibody and antibody.
-
Which are the major companies in the Microscopic Polyangiitis pipeline products market?
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.